142 related articles for article (PubMed ID: 29137822)
1. DNMT1 is associated with cell cycle and DNA replication gene sets in diffuse large B-cell lymphoma.
Loo SK; Ab Hamid SS; Musa M; Wong KK
Pathol Res Pract; 2018 Jan; 214(1):134-143. PubMed ID: 29137822
[TBL] [Abstract][Full Text] [Related]
2. DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas.
Loo SK; Ch'ng ES; Lawrie CH; Muruzabal MA; Gaafar A; Pomposo MP; Husin A; Md Salleh MS; Banham AH; Pedersen LM; Møller MB; Green TM; Wong KK
Pathology; 2017 Dec; 49(7):731-739. PubMed ID: 29074044
[TBL] [Abstract][Full Text] [Related]
3. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
[TBL] [Abstract][Full Text] [Related]
4. UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma.
Bedekovics T; Hussain S; Feldman AL; Galardy PJ
Blood; 2016 Mar; 127(12):1564-74. PubMed ID: 26702068
[TBL] [Abstract][Full Text] [Related]
5. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.
Yoon N; Ahn S; Yong Yoo H; Jin Kim S; Seog Kim W; Hyeh Ko Y
Oncotarget; 2017 Mar; 8(13):22014-22022. PubMed ID: 28423544
[TBL] [Abstract][Full Text] [Related]
6. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
[TBL] [Abstract][Full Text] [Related]
7. Microarray expression profiles of long non-coding RNAs in germinal center-like diffuse large B-cell lymphoma.
Gao HY; Wu B; Yan W; Gong ZM; Sun Q; Wang HH; Yang W
Oncol Rep; 2017 Sep; 38(3):1363-1372. PubMed ID: 28713985
[TBL] [Abstract][Full Text] [Related]
8. Microarray-based classification of diffuse large B-cell lymphoma.
Poulsen CB; Borup R; Nielsen FC; Borregaard N; Hansen M; Grønbaek K; Møller MB; Ralfkiaer E
Eur J Haematol; 2005 Jun; 74(6):453-65. PubMed ID: 15876249
[TBL] [Abstract][Full Text] [Related]
9. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
[TBL] [Abstract][Full Text] [Related]
10. Impact of dose-dense immunochemotherapy on prognosis of germinal center and non germinal center origin of diffuse large B cell lymphoma.
Rigacci L; Puccini B; Iovino L; Martelli M; Finolezzi E; DI Lollo S; Doria M; Bosi A
J Chemother; 2011 Aug; 23(4):227-31. PubMed ID: 21803701
[TBL] [Abstract][Full Text] [Related]
11. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
[TBL] [Abstract][Full Text] [Related]
12. AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines.
Jiao J; Lv Z; Zhang P; Wang Y; Yuan M; Yu X; Otieno Odhiambo W; Zheng M; Zhang H; Ma Y; Ji Y
Neoplasia; 2020 Mar; 22(3):142-153. PubMed ID: 32062068
[TBL] [Abstract][Full Text] [Related]
13. [Prevalence of germinal center B-cell-like and non-germinal center B-cell-like types of diffuse large B-cell lymphoma in Shanghai, China].
Chen Y; Chen H; Fu K; Zhu XZ; Irons R
Zhonghua Bing Li Xue Za Zhi; 2010 May; 39(5):313-8. PubMed ID: 20654154
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
[TBL] [Abstract][Full Text] [Related]
15. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.
Wright G; Tan B; Rosenwald A; Hurt EH; Wiestner A; Staudt LM
Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9991-6. PubMed ID: 12900505
[TBL] [Abstract][Full Text] [Related]
16. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.
Slack GW; Steidl C; Sehn LH; Gascoyne RD
Br J Haematol; 2014 Dec; 167(5):608-17. PubMed ID: 25135752
[TBL] [Abstract][Full Text] [Related]
17. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
Xia Y; Li ZM; Shi YX; Xia ZJ; Jiang WQ; Huang HQ
Ai Zheng; 2009 Feb; 28(2):146-9. PubMed ID: 19550126
[TBL] [Abstract][Full Text] [Related]
18. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
19. Enhanced DNA repair and genomic stability identify a novel HIV-related diffuse large B-cell lymphoma signature.
Maguire A; Chen X; Wisner L; Malasi S; Ramsower C; Kendrick S; Barrett MT; Glinsmann-Gibson B; McGrath M; Rimsza LM
Int J Cancer; 2019 Dec; 145(11):3078-3088. PubMed ID: 31044434
[TBL] [Abstract][Full Text] [Related]
20. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
